martes, 4 de marzo de 2025

Omalizumab treats multi-food allergy better than oral immunotherapy High rate of oral immunotherapy side effects in NIH trial explains superiority of omalizumab.

https://www.nih.gov/news-events/news-releases/omalizumab-treats-multi-food-allergy-better-oral-immunotherapy

No hay comentarios:

Publicar un comentario